Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $25.92 Consensus PT from Analysts

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $25.9167.

Several research firms have recently issued reports on RLAY. Citigroup reaffirmed a “market outperform” rating on shares of Relay Therapeutics in a research note on Monday, August 10th. Raymond James Financial restated a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. Guggenheim restated a “buy” rating on shares of Relay Therapeutics in a research report on Friday, August 7th. Zacks Research upgraded shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday, July 6th.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY opened at $18.66 on Thursday. The business’s 50 day simple moving average is $19.37 and its 200-day simple moving average is $15.34. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of -11.89 and a beta of 1.69. Relay Therapeutics has a 12 month low of $3.87 and a 12 month high of $21.27.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. On average, equities analysts anticipate that Relay Therapeutics will post -1.61 earnings per share for the current year.

Insider Activity

In other Relay Therapeutics news, CEO Sanjiv Patel sold 48,199 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.94, for a total transaction of $912,889.06. Following the completion of the transaction, the chief executive officer owned 519,500 shares of the company’s stock, valued at approximately $9,839,330. This trade represents a 8.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Peter Rahmer sold 4,508 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $20.03, for a total value of $90,295.24. Following the completion of the transaction, the insider directly owned 223,657 shares of the company’s stock, valued at approximately $4,479,849.71. This trade represents a 1.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,488,593 shares of company stock worth $125,133,958 in the last quarter. 5.04% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Relay Therapeutics during the first quarter worth about $34,000. Allworth Financial LP purchased a new position in shares of Relay Therapeutics during the second quarter valued at approximately $34,000. Smartleaf Asset Management LLC lifted its stake in shares of Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after buying an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Relay Therapeutics during the fourth quarter worth approximately $46,000. Finally, Captrust Financial Advisors acquired a new stake in Relay Therapeutics during the second quarter worth approximately $49,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.